

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application) PATENT APPLICATION
 Inventor(s): Vickers et al.)
 SC/Serial No.: 09/856,704) Art Unit: 1647
 Filed: July 18, 2001) Examiner: J. Seharaseyon
 Confirm. No: 2234)
 Title: TREATMENT OF HYPERTENSION)
 USING GROWTH HORMONE IN)
 MAMMALS SUBJECTED TO FETAL) Customer No: 23910
 PROGRAMMING)

CERTIFICATE OF FACSIMILE TRANSMISSION UNDER 37 C.F.R. § 1.8

I hereby certify that this correspondence is being transmitted by facsimile to the Commissioner for Patents, the United States Patent and Trademark Office, Examining Group 1647 Facsimile No. (703) 872-9306 on December 2, 2004.

D. Benjamin Borson (Attorney Signature)
 D. Benjamin Borson, Reg. No. 42,349
 Signature Date: December 2, 2004

RECEIVED
 CENTRAL FAX CENTER
 DEC 02 2004

File
 purpose
 only

REQUEST FOR CONTINUED EXAMINATION UNDER 37 C.F.R. § 1.114

Mail Stop RCE
 Commissioner for Patents
 P.O. Box 1450
 Alexandria, VA 22313-1450

Dear Sir:

Applicants hereby request continued examination of the above-identified utility patent application. The subject patent application was filed on or after June 8, 1995 and this paper is being filed prior to the earliest of: (1) Payment of the issue fee, unless a petition under 37 C.F.R. § 1.313 is granted; (2) abandonment of the application; or (3) the filing of a notice of appeal to the U.S. Court of Appeals for the Federal Circuit under 35 U.S.C. 141, or the commencement of a civil action under 35 U.S.C. 145 or 146, unless the appeal or civil action is terminated. 37 C.F.R. § 1.114(a).

Transmitted with this communication are the following:

X An Amendment or Response Under 37 C.F.R. 1.116.
X Applicant(s) qualify for small entity status under 37 C.F.R. § 1.27.

- 1 -

Attorney Docket No.: ERNZ 1003 US0 DBB
 446/ERNZ/1003 US0.011.RCE.wpd

107.002:123103
 12/02/04-08:33

PAGE 211 * RCVO AT 12/2/2004 11:39:17 AM [Eastern Standard Time] * SVR:USPTO-EFTRF-10 * DNS:8729306 * CSID:415 362 2928 * DURATION (mm:ss):03:08

12/13/2004 DUILLIA6 00000001 061325 09856704

01 FC:2001 395.00 DA

FEE VALUE ACCOUNTABILITY	
DEPOSIT ACCOUNT NO.	
06	1325
FEE CODE	VALUE DISTRIBUTED
2801	395.00

The fee associated with this communication has been calculated as shown below:

X A fee of \$395.00 is due pursuant to 37 C.F.R. §1.17(e) for the filing of this Request for Continued Examination.

_____ A fee for addition of claims under 37 C.F.R. §1.16 is due as follows:

FRES	Claims Retracting After Amendment	Highest Number Previously Paid For	Present Extra	Rate Small Entity/Other Than Small Entity	Total
TOTAL CLAIMS (37 C.F.R. 1.16(d))	18 **	28 **	—	X \$ 9.00 X \$ 18.00	\$ 0
INDEPENDENT CLAIMS (37 C.F.R. 1.16(d))	1 **	1 ***	—	X \$ 44.00 X \$ 88.00	\$ 0
FIRST PRESENTATION OF MULTIPLE DEPENDENT CLAIM PRESENT (37 C.F.R. 1.16(d))				+ \$150.00 + \$300.00	\$ 0
				TOTAL	\$ 0

* If the entry in column 1 is less than the entry in column 2, write "0" in column 3.

** If the "Highest Number of Previously Paid For" in this space is less than 20, enter "20".

*** If the "Highest Number Previously Paid For" in this space is less than 3, enter "3".

The total fee required with this communication is \$ 395 and is to be paid as follows:

X Please charge Deposit Account No. 06-1325 in the amount of \$395.

X The Commissioner is hereby authorized to charge any deficiencies or credit overpayment to Deposit Account No. 06-1325.

Respectfully submitted,

Date: December 2, 2004

By: D. Benjamin Borson
D. Benjamin Borson, Ph.D.
Reg. No. 42,349

FLIESLER MEYER LLP
Four Embarcadero Center, Fourth Floor
San Francisco, California 94111-4156
(415) 362-3800

- 2 -

Attorney Docket No.: ERNZ 1003 USO DBP
dbb/ERNZ/1003 USO/011.RCE.wpd

107.002:123103
12/02/04-08:46